37 related articles for article (PubMed ID: 12520826)
1. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.
Shah N; Li L; McCarty J; Kaur I; Yvon E; Shaim H; Muftuoglu M; Liu E; Orlowski RZ; Cooper L; Lee D; Parmar S; Cao K; Sobieiski C; Saliba R; Hosing C; Ahmed S; Nieto Y; Bashir Q; Patel K; Bollard C; Qazilbash M; Champlin R; Rezvani K; Shpall EJ
Br J Haematol; 2017 May; 177(3):457-466. PubMed ID: 28295190
[TBL] [Abstract][Full Text] [Related]
2. Outcomes in progressive systemic sclerosis treated with autologous hematopoietic stem cell transplantation compared with combination therapy.
Keret S; Henig I; Zuckerman T; Kaly L; Shouval A; Awisat A; Rosner I; Rozenbaum M; Boulman N; Dortort Lazar A; Molad Y; Sabbah F; Naffaa ME; Hardak E; Slobodin G; Rimar D
Rheumatology (Oxford); 2024 May; 63(6):1534-1538. PubMed ID: 37672021
[TBL] [Abstract][Full Text] [Related]
3. Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation.
Barajas Ordonez F; Wolleschak D; Zeller Y; Hinnerichs M; Rodríguez-Feria P; Aghayev A; Mikusko M; Borggrefe J; Mougiakakos D; Surov A
Leuk Lymphoma; 2024 Jun; 65(6):825-832. PubMed ID: 38384127
[TBL] [Abstract][Full Text] [Related]
4. Another quadruplet therapy for multiple myeloma: the beginning of the end for autologous haematopoietic stem-cell transplantation?
Callander NS
Lancet Haematol; 2024 Jun; 11(6):e392-e393. PubMed ID: 38677301
[No Abstract] [Full Text] [Related]
5. The Arkansas approach to therapy of patients with multiple myeloma.
Barlogie B; Anaissie E; van Rhee F; Pineda-Roman M; Zangari M; Shaughnessy J; Epstein J; Crowley J
Best Pract Res Clin Haematol; 2007 Dec; 20(4):761-81. PubMed ID: 18070718
[TBL] [Abstract][Full Text] [Related]
6. Multiple myeloma in Nigeria: a multi-centre epidemiological and biomedical study.
Nnonyelum ON; Anazoeze MJ; Eunice NO; Emmanuel OO; Stella AT; Marcus AI; Taiwo BM; Olufela KO; Chinawaeze AJ; Orkuma JA; Dalhat GG; Otobo UI
Pan Afr Med J; 2015; 22():292. PubMed ID: 26966488
[TBL] [Abstract][Full Text] [Related]
7. A way forward on the medically appropriate use of white cell growth factors.
Smith TJ; Hillner BE
J Clin Oncol; 2012 May; 30(14):1584-7. PubMed ID: 22370327
[No Abstract] [Full Text] [Related]
8. Treatment of multiple myeloma.
San Miguel JF; Bladé Creixenti J; García-Sanz R
Haematologica; 1999 Jan; 84(1):36-58. PubMed ID: 10091392
[TBL] [Abstract][Full Text] [Related]
9. The role of high-dose chemotherapy in the treatment of multiple myeloma: a controversy.
Kyle RA
Ann Oncol; 2000; 11 Suppl 1():55-8. PubMed ID: 10707780
[TBL] [Abstract][Full Text] [Related]
10. High-dose therapy followed by autologous haematopoietic stem cell transplantation in multiple myeloma.
Koh LP; Linn YC; Teoh G; Goh YT; Tan PH
Ann Acad Med Singap; 2002 Nov; 31(6):731-7. PubMed ID: 12520826
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the feasibility and efficacy of autologous stem cell transplantation in elderly patients with multiple myeloma.
Muta T; Miyamoto T; Fujisaki T; Ohno Y; Kamimura T; Kato K; Takenaka K; Iwasaki H; Eto T; Takamatsu Y; Teshima T; Akashi K;
Intern Med; 2013; 52(1):63-70. PubMed ID: 23291675
[TBL] [Abstract][Full Text] [Related]
12. Maintenance therapy with thalidomide improves overall survival after autologous hematopoietic progenitor cell transplantation for multiple myeloma.
Brinker BT; Waller EK; Leong T; Heffner LT; Redei I; Langston AA; Lonial S
Cancer; 2006 May; 106(10):2171-80. PubMed ID: 16598756
[TBL] [Abstract][Full Text] [Related]
13. Busulfan, Melphalan, and Bortezomib versus High-Dose Melphalan as a Conditioning Regimen for Autologous Hematopoietic Stem Cell Transplantation in Multiple Myeloma.
Rodriguez TE; Hari P; Stiff PJ; Smith SE; Sterrenberg D; Vesole DH
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1391-1396. PubMed ID: 27164062
[TBL] [Abstract][Full Text] [Related]
14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
[TBL] [Abstract][Full Text] [Related]
15. CD34+ hematopoietic progenitor cell dose as a predictor of engraftment and survival in multiple myeloma patients undergoing autologous stem cell transplantation.
Aladağ Karakulak E; Demiroğlu H; Büyükaşik Y; Turgut M; Aksu S; Sayinalp N; Haznedaroğlu IC; Özcebe OI; Göker H
Turk J Med Sci; 2020 Dec; 50(8):1851-1856. PubMed ID: 32512672
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
